US-based biotech firm Intrexon has partnered with Sanofi Chimie to develop an effective production process for a specific family of its marketed active pharmaceutical ingredients (APIs).
The companies have signed an exclusive channel collaboration (ECC) to enhance and optimise APIs production process by using its current manufacturing operations in France.
As part of the deal, Intrexon will use Sanofi’s advanced computational biology and bioinformatics to identify the efficient biological pathways to produce marketed APIs.
The industrial product division facilities of Intrexon, located in Hungary and California, will develop and synthesise new components to drive optimal output from constructed cell lines.
Intrexon chairman and CEO Randal Kirk said: "We are excited to partner with Sanofi to improve existing fermentation processes, providing a competitive advantage in marketed APIs production.
"We are confident that our synthetic biology expertise and robust technology platforms will drive development of Sanofi’s next-generation strain in a commercially feasible way that also produces the highest possible yields."
Intrexon noted that collaboration will leverage its proprietary technology suite, as well as Sanofi’s expertise and innovation in yeast metabolism and industrial chemistry to increase overall yield.
Intrexon plans to provide its new BeyondBio platform to Sanofi for accessing extensive library of characterised genetic components, which facilitates customised gene design and high-throughput modular DNA assembly.
The company, through its UltraVector platform and suite of technologies, helps its partners in the industrial-scale design and development of complex biological systems.